AI Rating
Rating methodologyLatest close (chg%)391.62-1.34%
Buy price
370.00
Target price500.00
Sell price340.00
P/E TTM40.19
P/E38.72
Confidence65%
Risk score60/100
AI Summary
The stock presents a compelling AI/Terafab growth narrative but is currently overvalued with weak trend momentum (low ADX) and high profit-taking risk. The prudent strategy is to wait for a pullback to a better risk/reward entry point with confirming trend strength.